Skip to main content
. 2020 Sep 17;5(18):e137646. doi: 10.1172/jci.insight.137646

Figure 2. Amelioration of cranial doming by P15 in hydrocephalic Tmem67–/– rats by treatment with TRPV4 antagonist (RN 1734).

Figure 2

(A and B) Vertical and horizontal dimensions of normal (Tmem67+/+, Tmem67+/–) and hydrocephalic (Tmem67–/–) rats taken at P15 after 7 days daily i.p. treatment with either vehicle or RN 1734 (TRPV4 antagonist). (C) BWs of normal and hydrocephalic rats taken at P15 after 7 days daily i.p. treatment with either vehicle or RN 1734. Normal, vehicle (n = 26); normal, RN 1734 (n = 13). Hydro, vehicle (n = 5); hydro, RN 1734 (n = 4). All data shown are the mean ± SEM for each group. Significance values were determined by 2-way ANOVA test in Prism using genotype and treatment as variables. Vehicle, DMSO/saline injection; RN 1734, RN 1734, TRPV4 antagonist, 4 mg/kg BW i.p. daily injection.